Other notable targets being investigated in the STS realm include NTRK fusion in CD34-positive fibrosarcomas of bone and soft tissue [101,102,103], EZH2/INI1 loss (epithelioid sarcomas, rhabdoid tumors) [104], and ALK fusion in inflammatory myofibroblastic tumors [105]. Here, SMARCB1 is linked to epithelioid sarcoma.